Scores by kind of claim
Each kind of claim is scored on its own, out of 100: the share that held up, with the range it likely falls in. Fewer resolved claims give a wider range.
-
Factual claims
Statements about the present or the past, checked against the record: did they hold up?
76 70 81 -
Predictions
Statements about events outside the person's control, checked once they fell due: did they come true?
68 54 82 -
Promises
Commitments to the person's or organisation's own future action, with something to deliver: was it delivered?
Insufficient record: 3 promises resolved, 5 needed for a score.
All types combined: 74 (likely 69 to 80, high confidence), from 96 claims: 82 factual claims, 14 predictions. It mixes kinds of claim in different proportions for different people, so compare people kind by kind.
Bill Ackman's claims
135 claims · page 2 of 2
“Our most glaring, albeit small, unforced error was buying additional stock in Platform Specialty Products at $25 per share to assist the company in financing an acquisition.”
Bill Ackman, Pershing Square letter author January 2016 Bill Ackman's Pershing Square Annual Investor Letter (2015 letter) (GuruFocus)
Pershing Square bought additional Platform Specialty Products stock at $25 per share to help the company finance an acquisition.
Unresolvable The public record could not settle it.
Said for an organisation they lead or work for; it counts on both records.
What would count as true or false
Judged as of January 2016. True: records show Pershing Square funds bought additional Platform Specialty Products (PAH) shares at $25 per share in a placement or offering whose stated purpose was to help finance an acquisition (e.g. the 2015 equity raise tied to the Arysta LifeScience or Alent deals). Mostly true: such a purchase took place to fund an acquisition, but the price differs slightly from $25 (within about $1 per share) or a minor detail, such as which acquisition, is off. Mixed: Pershing bought more shares around that time, but either the $25 price or the acquisition-financing purpose is clearly wrong. Mostly false: Pershing bought PAH shares, but not as an extra purchase in a company financing, or at a price very different from $25. False: records show Pershing bought no additional PAH stock in any such financing.
Evidence
- Chemical Week • October 6/13, 2014 • 9 Chemical Week (IHS) · October 2014
“On 6 October, Platform announced it is issuing up to $651.6 million, or about 25.5 million shares, in common stock in a private placement at $25.59/share.”
- Chemical Week • October 6/13, 2014 • 9 Chemical Week (IHS) · October 2014
“Platform’s largest shareholders are hedge funds Pershing Square and Stanhope Investments, which combined own about 40% of the company.”
- Chemical Week • October 6/13, 2014 • 9 IHS Chemical Week · October 2014
“On 6 October, Platform announced it is issuing up to $651.6 million, or about 25.5 million shares, in common stock in a private placement at $25.59/share.”
- Chemical Week • October 6/13, 2014 • 9 IHS Chemical Week · October 2014
“Platform’s largest shareholders are hedge funds Pershing Square and Stanhope Investments, which combined own about 40% of the company.”
- Hedge Fund Billionaire Bill Ackman Admits He Made Mistakes | Fortune Fortune · 27 January 2016
“and he said it was a mistake to buy more shares in Platform Specialty Products (PAH) at $25 a share to help the company finance an acquisition.”
- Platform Specialty Products Corporation Announces Pricing of ... Platform Specialty Products Corporation (SEC Exhibit 99.2, GLOBE NEWSWIRE release) · 6 October 2014
“for the purchase of a total of 25,465,024 shares of its common stock (the "Shares") for an aggregate purchase price of $651.6 million, or $25.59 per Share (the closing sale price per share on the New York Stock Exchange on October 2, 2014).”
- Platform Specialty Products Corporation Announces Pricing of ... Platform Specialty Products Corporation (SEC Exhibit 99.2, GLOBE NEWSWIRE release) · 6 October 2014
“Platform intends to use the net proceeds from this private placement for general working capital, including repayment of debt incurred in connection with the previously-announced acquisition of Chemtura Corporation's AgroSolutions business, if completed.”
- UNITED STATES Platform Specialty Products Corporation (Form 10-K for fiscal year 2015)
“In connection with the Alent Acquisition, on December 2, 2015, the Company issued 18,419,738 shares of Platform's common stock to Alent shareholders, including Cevian Capital II Master Fund LP, the then largest shareholder of Alent.”
Reasoning
Platform's release (E8, E9) and Chemical Week (E2) record an October 2014 private placement at $25.59 per share. The October 2014 release says the private placement was priced at $25.59 per share and that the proceeds would be used for general working capital, including repaying debt tied to the Chemtura AgroSolutions acquisition if completed [E8][E9]. This is broadly consistent with an acquisition-financing purpose at a price close to $25, but the release does not say that Pershing Square bought shares in the placement. However, none of these sources names the buyers, and E3/E6 only say that Pershing Square was one of Platform's largest shareholders. The only link between Pershing and the purchase is Fortune's account of Ackman's own statement (E7), which repeats the subject's claim rather than confirming it.
Cite this claim
Bill Ackman, “Pershing Square bought additional Platform Specialty Products stock at $25 per share to help the company finance an acquisition.” (said January 2016). Verdict: unresolvable. Reliability API, claim c_1a9995ce4767, method 0.1.0+c876030c. https://epistacklabs.com/claims/c_1a9995ce4767
Claims without a verdict
- Unresolvable 135
- Not yet due 9
- Own records only 29
- Not researched 162
- Not checkable 431
Is a verdict here wrong, or do you speak for Bill Ackman? Reply on the claim's own page, with the form at its foot (how replies work). Verdicts are made automatically; how verdicts and scores are made.